Announced Mon, 6 Jul · 17:38 IST
Natco Pharma designates two senior officials for R&D roles
Management Changes View source PDF
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.8%1-day move
₹931.05
prior close
₹934.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-0.9-1.0-0.1+3.8+3.3+5.6+5.2+4.4+3.7————
Up moveDown movePending
AI summary
Natco Pharma has designated two officials in its R&D division effective 6th July 2026. Mr. Gnanadeva Chalapathy Gudipati is now Senior Vice President for Analytical Research and Development, while Mr. Madhava Rao Karicherla is Vice President for Formulation Research and Development at the Kothur Unit. Both appointments are under the company's standard policy terms.
Likely market impact
Routine internal senior management designation in R&D; minimal direct impact on shareholders or stock price.